Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Pancreatic Neoplasms 4Ovarian Neoplasms 2Lung Neoplasms 2Carcinoma, Ovarian Epithelial 2Urinary Bladder Neoplasms 1Urethral Neoplasms 1Unspecified Adult Solid Tumor, Protocol Specific 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Sarcoma 1Renal Insufficiency 1Recurrence 1Rectal Neoplasms 1Neoplasms 1Melanoma 1Liver Diseases 1Leiomyosarcoma 1Gliosarcoma 1Glioblastoma 1Gastrointestinal Stromal Tumors 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Adenocarcinoma Of Esophagus 1Adenocarcinoma 1

Interventions

Dexamethasone 13Bortezomib 8Cyclophosphamide 6Lenalidomide 4pomalidomide 3isatuximab 3Kidney Transplantation 3Calcium Dobesilate 3glucarpidase 2Thalidomide 2Paclitaxel 2Gemcitabine 2Carboplatin 2Bendamustine Hydrochloride 2Azacitidine 2vinflunine 1veliparib 1trifluridine tipiracil drug combination 1trebananib 1safinamide 1sacubitril and valsartan sodium hydrate drug combination 1rubitecan 1ripretinib 1regorafenib 1pevonedistat 1pembrolizumab 1osimertinib 1mirabegron 1melflufen 1gamma-Glutamyl Hydrolase 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Renal Insufficiency × rubitecan × Clear all
NCT00113113 2024-08-02

Study of Rubitecan in Cancer Patients With Renal or Hepatic Dysfunction

Astex Pharmaceuticals, Inc.

Phase 1 Completed
54 enrolled

Liver Diseases, Neoplasms, Renal Insufficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡